AMICUS THERAPEUTICS, INC. (FOLD) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, AMICUS THERAPEUTICS, INC.'s filing signal continuing positive.

Amicus Therapeutics is a global biotechnology company focused on developing and delivering transformative medicines for rare diseases. The company's two marketed therapies are Galafold(R), an oral monotherapy for Fabry disease, and Pombiliti(R) + Opfolda(R), a two-component treatment for late-onset Pompe disease. Galafold(R) is approved in over 40 countries, while Pombiliti(R) + Opfolda(R) is approved in the U.S., EU, UK, Canada, Australia, Switzerland, and Japan. Amicus also holds U.S. commercialization rights for DMX-200, a Phase 3 drug candidate for Focal Segmental Glomerulosclerosis. The company is currently operating under a definitive merger agreement with BioMarin Pharmaceutical Inc., expected to close in the second quarter of 2026.

Revenue is primarily driven by sales of Galafold(R) for Fabry disease and Pombiliti(R) + Opfolda(R) for Pompe disease. The company also has potential future revenue from its licensed DMX-200 program.